John Josephson, MD
Ophthalmology · Fairfax, VANPI 1154588374
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (59.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Bausch & Lomb Americas Inc. accounts for 60.2% of it on its own, with 22 other manufacturers making up the rest. 2025 is the largest year on record at $14,307, more than ten times the $492 reported in 2019. Among ophthalmology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 103 payments — averaging $230.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$14K
- Carl Zeiss Meditec USA, Inc.$4K
- Ziemer USA$1K
- Alcon$1K
- Rxsight Inc$1K
- NEW World Medical,inc.$497
- plus $1K from 17 others
Across 7 payments — averaging $10,071 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rxsight Inc$71K
What the payments were for
- Consulting fees$14,02559%
- Speaking & faculty fees$1,4266%
- Travel & lodging$3,49015%
- Food & beverage$4,77020%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 8 | $14,289 |
| Carl Zeiss Meditec USA, Inc. | 8 | $3,642 |
| Ziemer USA | 1 | $1,400 |
| Alcon | 31 | $1,311 |
| Rxsight Inc | 11 | $1,226 |
| NEW World Medical,inc. | 3 | $497 |
| Tarsus Pharmaceuticals, Inc. | 7 | $339 |
| Glaukos Corporation | 7 | $291 |
| Merz North America, Inc. | 1 | $160 |
| Dompe US, Inc. | 5 | $128 |
| Biotissue Holdings Inc. | 6 | $113 |
| Carl Zeiss Meditec, Inc. | 1 | $65 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $43 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $43 |
| Kala Pharmaceuticals, Inc. | 2 | $37 |
| Harrow Eye, LLC | 1 | $27 |
| AbbVie | 1 | $20 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Sight Sciences, Inc. | 1 | $17 |
| Lensar, Inc. | 1 | $16 |
| Novartis | 1 | $15 |
| Oyster Point Pharma, Inc. | 1 | $15 |
| Sun Pharmaceutical Industries Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CIRRUS HD-OCT$3,436
- IOLMaster 700$3,436
- VERACITY SURGICAL$3,436
- VisuMax$3,436
- ARTEVO 800$1,813
- FEMTOLDV$1,400
- RXSIGHT CONTACT LENS$703
- RXSIGHT INJECTOR CARTRIDGE$703
- RXSIGHT INJECTOR HANDPIECE$703
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$703
- LIGHT ADJUSTABLE LENS (LAL)$563
- AcrySof IQ PanOptix$297
- Clareon$285
- Kahook Dual Blade$280
- Streamline Surgical System$280
- Ahmed Glaucoma Valve$280
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$246
- enVista MX60 IOL$150
- XDEMVY$142
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$140
How this compares
$23,730 in reported general payments places this provider in the 95th percentile of 509 ophthalmology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 33 | $36,578 |
| XdemvyLotilaner | 11 | $20,115 |
| ValacyclovirValacyclovir Hcl | 12 | $1,306 |
| Prednisolone Acetate | 28 | $1,154 |
| Doxycycline Hyclate | 24 | $493 |
| MoxifloxacinMoxifloxacin Hcl | 12 | $300 |
| Latanoprost | 18 | $205 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 12 | $125 |
| Timolol Maleate | 14 | $112 |
| Losartan Potassium | 13 | $73 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $20 | $36,57833 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $339 | $20,11511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 509 ophthalmology providers in Virginia.
Other ophthalmology in Fairfax
- Ethnie JonesRichmond$2M
- Elizabeth Yeu-LinNorfolk$1.7M
- John SheppardNorfolk$1.1M
- Constance OkekeNorfolk$800K
- Marc OdrichCharlottesville$497K
- Jayakrishna AmbatiCharlottesville$116K
- Thomas JolyNorfolk$95K
- Stephen ScoperNorfolk$88K
- Leonard RappaportPortsmouth$85K
- Soheila RostamiReston$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.